Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RETENTION: Benralizumab for Alpelisib Rash Prevention
NCT05966584Phase 2Terminated
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Jul 2023
- Primary completion
- Aug 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of benralizumab in drug eruption, sponsored by Memorial Sloan Kettering Cancer Center. Started Jul 2023; status: terminated.
02
Drugs
benralizumab
03
Conditions
drug eruption
Beyond the preview
Go deeper on NCT05966584.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05966584.